Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Condition(s) studied
Investigational drug(s) / intervention(s)
Serum endocan: Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Serum copeptin: Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Study summary
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Eligibility
Primary outcome measure(s)
- Serum endocan level for prediction of severity of respiratory distress syndrome — First day of life
Serum endocan level for prediction of severity of respiratory distress syndrome (RDS) will be recorded.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tanta University | Tanta | El-Gharbia | Recruiting |
More Tanta University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07154134 on ClinicalTrials.gov ↗ ← All trials in Egypt